July 9, 2024
|
Abata News
Abata Therapeutics Announces FDA Clearance of Investigational New Drug Application for Clinical Evaluation of ABA-101 in Progressive Multiple Sclerosis
August 28, 2023
|
Abata News
Abata Therapeutics to Present and Participate in Upcoming Investor and Industry Events
August 24, 2023
|
Abata News
Abata Therapeutics Announces Second Development Candidate, ABA-201, a Novel Treg Cell Therapy for the Treatment of Type 1 Diabetes
May 31, 2023
|
Abata News
Abata Therapeutics to Present at Upcoming Investor and Industry Events in June
April 20, 2023
|
Abata News
Abata Therapeutics Announces the Appointment of Leonard Dragone, M.D., Ph.D., as Chief Medical Officer
March 9, 2023
|
Abata News
Abata Therapeutics Appoints David Kaufman, M.D., Ph.D., to its Board of Directors